Editing GSK-3 (section)

===Specific agents===
Inhibitors of GSK-3 include:<ref name="pmid31553649">{{cite journal | vauthors = Noori MS, Bhatt PM, Courreges MC, Ghazanfari D, Cuckler C, Orac CM, McMills MC, Schwartz FL, Deosarkar SP, Bergmeier SC, McCall KD, Goetz DJ | display-authors = 6 | title = Identification of a novel selective and potent inhibitor of glycogen synthase kinase-3 | journal = American Journal of Physiology. Cell Physiology | volume = 317 | issue = 6 | pages = C1289–C1303 | date = December 2019 | pmid = 31553649 | pmc = 6962522 | doi = 10.1152/ajpcell.00061.2019 }}</ref><ref name="pmid27902447">{{cite journal | vauthors = Licht-Murava A, Paz R, Vaks L, Avrahami L, Plotkin B, Eisenstein M, Eldar-Finkelman H | title = A unique type of GSK-3 inhibitor brings new opportunities to the clinic | journal = Science Signaling | volume = 9 | issue = 454 | pages = ra110 | date = November 2016 | pmid = 27902447 | doi = 10.1126/scisignal.aah7102 | s2cid = 34207388 }}</ref><ref name="pmid22065134">{{cite journal | vauthors = Eldar-Finkelman H, Martinez A | title = GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS | journal = Frontiers in Molecular Neuroscience | volume = 4 | pages = 32 | year = 2011 | pmid = 22065134 | pmc = 3204427 | doi = 10.3389/fnmol.2011.00032 | doi-access = free }}</ref><ref name="pmid24931005">{{cite journal | vauthors = McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Sokolosky M, Abrams SL, Montalto G, D'Assoro AB, Libra M, Nicoletti F, Maestro R, Basecke J, Rakus D, Gizak A, Demidenko ZN, Cocco L, Martelli AM, Cervello M | display-authors = 6 | title = GSK-3 as potential target for therapeutic intervention in cancer | journal = Oncotarget | volume = 5 | issue = 10 | pages = 2881–2911 | date = May 2014 | pmid = 24931005 | pmc = 4102778 | doi = 10.18632/oncotarget.2037 }}</ref>
{{div col|colwidth=22em}}